1st Order Pharmaceuticals Inc: 1OP-2198

Discussion in 'Research News' started by Mic, Jan 25, 2017.

    1. Autumnly
      Wishful

      Autumnly Member Podcast Patron Benefactor Ambassador Hall of Fame Advocate

      Tinnitus Since:
      2013
      Cause of Tinnitus:
      Noise-induced
      Xenon Announces Final Results of XEN1101 Phase 1 Clinical Trial and Update on XEN901 Phase 1 Clinical Trial at the American Epilepsy Society (AES) Annual Meeting
      • XEN1101 is a Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders
      • Xenon today outlined plans for a XEN1101 Phase 2 clinical trial, with patient enrollment expected to begin early in the new year
      • Pharmacokinetics: The PK profile of XEN1101 (including an effective half-life greater than 24 hours) supports a once-per-day dosing schedule with expected steady state in approximately one week without the need for titration
      • Safety: The majority of adverse events (AEs) were mild or moderate, resolved spontaneously and were consistent with antiepileptic drugs of this class. Sedation (including somnolence, drowsiness) and dizziness (including light-headedness and presyncope) were the most common AEs, while mild cognitive effects (memory and speech impairment) and blurred vision were also observed in a dose dependent manner. There were no SAEs, deaths, or clinically significant ECG or laboratory findings. Phase 1 results suggest that that XEN1101 is generally safe and well tolerated in the doses examined (single doses of up to 30 mg and multiple doses of up to 25 mg once daily).
      About the XEN1101 Phase 2 Clinical Trial
      • patient enrollment expected to begin early in 2019
      • randomized, double-blind, placebo-controlled, multicenter study to evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive treatment in adult patients aged 18 to 75 years diagnosed with focal epilepsy
      • Approximately 300 patients
      • After screening, patients will have 8 weeks of baseline to assess frequency of seizures, followed by 8 weeks of treatment and a 4-week post treatment follow-up period
       
      • Informative Informative x 4
      • Like Like x 2
    2. Deamon22

      Deamon22 Member Podcast Patron Benefactor Ambassador

      Tinnitus Since:
      06/2018
      Cause of Tinnitus:
      Head Trauma/Cold?
      @Autumnly thank you for providing updates:)
       
    3. friend74
      Doubtful

      friend74 Member

      Location:
      Germany
      Tinnitus Since:
      1994
      Cause of Tinnitus:
      Loud Music
      Are there any (hopefully good) news regarding the latest trials or the drug itself?
       
      • Good Question Good Question x 2
      • Like Like x 1
    4. Autumnly
      Wishful

      Autumnly Member Podcast Patron Benefactor Ambassador Hall of Fame Advocate

      Tinnitus Since:
      2013
      Cause of Tinnitus:
      Noise-induced
      XEN1101 (in Phase 2)
      • Dr. Pimstone continued, “Within our XEN1101 ‘X-TOLE’ Phase 2b clinical trial, as with other trials ongoing in our industry, we are seeing a significant reduction in new patient enrollment for numerous reasons related to the COVID-19 pandemic; therefore, we have adjusted guidance with topline data now anticipated in the first half of 2021, which is, of course, dependent upon the rate of patient enrollment throughout the remainder of this year. Despite this shift in guidance, we are pleased with our progress in the X-TOLE study to date.
      • We are particularly encouraged by our review of safety data on a blinded basis, which suggests that XEN1101 is currently being well tolerated. The rate of discontinuations to date in the study is lower than modeled. Of note, to date, more than 90% of subjects from the double-blind portion of the trial have entered the open-label extension phase. Based on this review of blinded safety data to date, we believe tolerability is well within the modeled parameters, and, therefore, we do not believe an interim analysis is required. Our goal is to complete the study, as planned, in the shortest possible time frame.
      • source
      XEN496 (Phase 3 anticipated to start in 2020)
      • U.S. Food and Drug Administration (FDA) recently granted Fast Track designation for the investigation of XEN496 for the treatment of seizures related to KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE)
      • Feedback from the FDA regarding the Phase 3 clinical trial design is expected in the second quarter of 2020, and the Phase 3 clinical trial in KCNQ2-DEE is anticipated to start in 2020, dependent upon the ability to initiate clinical sites and patient enrollment given the ongoing COVID-19 pandemic.
      • Dr. Pimstone added, “We are also pleased to report that we recently completed a pharmacokinetic, or PK, study testing XEN496, our proprietary pediatric formulation of ezogabine, in healthy adult volunteers. The PK profile observed for XEN496 appears to be comparable to historical PK data for immediate-release ezogabine tablets, with XEN496 showing similar absorption and elimination curves, and we are excited that these data support Xenon’s planned Phase 3 clinical trial of XEN496 in patients with KCNQ2-DEE.
      • source
       
      • Informative Informative x 5
      • Like Like x 1
    5. UHPTS
      Wishful

      UHPTS Member

      Tinnitus Since:
      October 2019
      Cause of Tinnitus:
      Ear infection
      Let's assume that FDA approves XEN-496. Does that approval apply to European countries as well? What is the mechanism?
       
      • Good Question Good Question x 1
    6. Lucifer

      Lucifer Member Podcast Patron Benefactor

      Tinnitus Since:
      2017
      Cause of Tinnitus:
      Ear Infection
      Out of those two which one was the Trobalt reformulation?
       
    7. Greg Sacramento

      Greg Sacramento Member Benefactor Hall of Fame

      Tinnitus Since:
      April 2011
      Cause of Tinnitus:
      syringing and now somatic T dental work
      There's about 600 bio tech public trading companies that are working on conditions that relate to a cause of tinnitus. Many bio tech companies have associated researchers where some their names have been mentioned here. The tinnitus space is well managed by money management.

      I like Xenon. Bio tech managers and their medical researchers have become a little concerned with blurry vision. The stock price has dropped a bit.

      I also like VistaGen. The stock price is under a dollar. It they hit goals, stock price will rocket. If not, then it will probably be worth less. https://www.vistagen.com/pipeline
       
      • Informative Informative x 2
    8. Mathew Gould

      Mathew Gould Member Benefactor

      Tinnitus Since:
      6/2017
      Cause of Tinnitus:
      Neck/Jaw misalignment
      600 companies... You would think 1 could get lucky with tinnitus in the next 2-3 years or sooner.
       
      • Agree Agree x 1
    9. UHPTS
      Wishful

      UHPTS Member

      Tinnitus Since:
      October 2019
      Cause of Tinnitus:
      Ear infection
      Both, I think.
       
    10. Greg Sacramento

      Greg Sacramento Member Benefactor Hall of Fame

      Tinnitus Since:
      April 2011
      Cause of Tinnitus:
      syringing and now somatic T dental work
      They have FDA fast track.
      Read the information in the dark blue area within this link. The publication research support section will take hours to read.

      Their research on ion channels and receptors is amazing.

      AV -101 might just replace benzos, antidepressants and anticonvulsants (such as gabapentin and pregabalin). No taper is needed.
      https://www.vistagen.com/pipeline/av-101/neuropathic-pain

      I expect that they will offer more stock shares and then money management will take positions.
       
      • Like Like x 2
    11. UHPTS
      Wishful

      UHPTS Member

      Tinnitus Since:
      October 2019
      Cause of Tinnitus:
      Ear infection
      For AV-101 I only found one mention on tinnitus in this document:

      https://ir.vistagen.com/all-sec-filings/content/0001654954-20-007107/0001654954-20-007107.pdf

      They received fast track for AV-101 back in 2018, whatever that means for the drug to hit the market.
       
    12. Utopia

      Utopia Member

      Tinnitus Since:
      1997, then resolved til recent worsening
      Cause of Tinnitus:
      Concert, Acoustic Trauma
       
    13. Greg Sacramento

      Greg Sacramento Member Benefactor Hall of Fame

      Tinnitus Since:
      April 2011
      Cause of Tinnitus:
      syringing and now somatic T dental work
      @Utopia There is no official list. These are companies that I have found by researching. It would be hard to keep an updated list as that would be too time consuming. Some companies are working on medical conditions such as jaw and neck diseases that may cause a very small percentage tinnitus. Some others are working on medical conditions that may have effect from having tinnitus such as anxiety and eye problems.

      Above, less than two weeks ago, I mentioned VistaGen, a company that has been around for a long time. The volume started to increase and price has climbed from 44 cents to 75 cents. Today a wealth management firm said that the stock should reach 3.00 a share. The price for a few minutes increased to 95 cents, but soon came back down to 75 cents. It appears that this firm had preloaded clients over the last ten days and did a pump and dump as large sell asks were already into the system. VistaGen has the FDA go ahead for a Phase III study and if they are successful, then price will ready rocket.

      Wealth management is deep into the tinnitus and medical space as their goal is to get clients and make money. Most in the tinnitus space are wealth management players, and this makes it difficult to know what treatments and advice may be for real and not just the wind blowing.
       
      • Optimistic Optimistic x 1
      • Creative Creative x 1
    14. tommyd87

      tommyd87 Member

      Tinnitus Since:
      1999
      Cause of Tinnitus:
      tmj music
      There will be some success soon with this treatment. This is inevitably why we are seeing wealth firms invest in this industry in droves. It will lead to big benefits financially when something is found particularly in the restoration of hearing arm.
       
      • Useful Useful x 1
    15. Greg Sacramento

      Greg Sacramento Member Benefactor Hall of Fame

      Tinnitus Since:
      April 2011
      Cause of Tinnitus:
      syringing and now somatic T dental work
      @tommyd87

      Not sure why you gave me a creative rating for my post above, but I agree that lots of medical discoveries have been made as I have posted about that many times. The company that I mentioned above has seen a nice price increase since my first mention, but today in after hours it took a little hit because of a recent share offering that was previously known to seasonal investors. This company has a sales and research agreement with another firm that's not a good profit deal. What I care about is their research for anxiety and pain and hoping for products to come to market..

      Been doing medical research and investing in medical since the 70's. I have degrees in both areas, but that is worth about two cents. Caution is always needed with the smaller bio techs. For smaller bio techs, reverse splits, increased creative financing and issue of more shares is almost always hurtful to investors. Everyday of the trading week, within minutes, there's several bio techs that increase 50%, 100% or more in price. Some continue to go up and others will fall back down and sometimes very quickly.
       
    16. tommyd87

      tommyd87 Member

      Tinnitus Since:
      1999
      Cause of Tinnitus:
      tmj music
      I didn't mean to give that rating, it wasn't intentional lol. That makes sense about the investment information. It is I guess why when we see shares for certain products fall somewhat significantly it can often be just for market related moves like changes in management, deals and profits/losses and nothing else.
       
    17. Paulmanlike

      Paulmanlike Member Podcast Patron Benefactor Hall of Fame

      Tinnitus Since:
      2008
      Cause of Tinnitus:
      Noise
      Would you personally buy into this company giving what you know?

      I saw their pipeline and the statement that it could replace antidepressants and benzos is amazing (if it happens).

      Very cautious with these penny stocks, it's not investing, it's more like gambling.
       
    18. Greg Sacramento

      Greg Sacramento Member Benefactor Hall of Fame

      Tinnitus Since:
      April 2011
      Cause of Tinnitus:
      syringing and now somatic T dental work
      No, not yet. They announced a share offering after the close on Friday. A share offering was filed with the SEC in October of last year, but only corporate, their underwriter and the SEC knew of date for share offering. I believe it will be 14 million shares. This would amount to 25% of the shares outstanding. Existing shareholders will be diluted by 25%. The offering probably will be at $0.69 or $0.70 which is a 25% discount from Friday's close of $0.92. The stock traded as low as $0.70 in Friday's after hours trading, which is independent from where it will open in Monday's pre market. The first hour of pre market trading for any stock is for investment funds only, although some stocks now trade 24 hours.

      Many that will grab these shares will be hedgers who already have put options. It will take a month before a wash is completed.

      After that, a reverse spilt may be needed to get a Nasdaq listing. The reserve spilt may be one share for every ten shares owned. Converted price in the area of 10 to 11 dollars per share. Dollar to dollar, one's total investment will remain the same - meaning no investment loss.

      After all this, then yes, I probably would consider buying. Their meds if approved for anxiety may replace antidepressants and benzos. No taper, not even a day is said to be needed, even with neuro disease. They have FDA fast track on one, and were given the go ahead for phase III. Their neuro brain research is incredible. I read their research papers with patent discovery of a pathway or gateway to the brain in attempt to cure neuro diseases. They are using this pathway with their present phase medications. They are also working on a pain med that will also use the same pathway to the brain.

      I can give you other bio techs that are still very low in price, some under a dollar that may really explode in price.
       
      • Like Like x 2
      • Good Question Good Question x 1
      • Informative Informative x 1
    19. grate_biff
      Alone

      grate_biff Member Benefactor

      Location:
      Moss, Norway
      Tinnitus Since:
      09/2014
      Cause of Tinnitus:
      Acoustic trauma and or benzo withdrawal
      Wow, this is really interesting and relevant to me as I´m taking two ADs, Gabapentin and suffer from benzo withdrawal.

      Do you mean one does not have to taper these drugs and switch to AV-101 without withdrawal or do you mean you can taper off of AV-101 without tapering?

      Thank you @Greg Sacramento for having so much knowledge about this med:)
       
      • Like Like x 1
    20. Paulmanlike

      Paulmanlike Member Podcast Patron Benefactor Hall of Fame

      Tinnitus Since:
      2008
      Cause of Tinnitus:
      Noise
      Greg thank you very much for your well informed posts as usual.
      I would be interested in the biotechs you talk about for some high risk stock picks.

      I am pretty impressed by the information. This also interests me from a patient view point. I have issues with OCD and had a depressive episode in 2017. I take regular AD's for this and have had to resort to benzos in the past.

      I will definitely be keeping a close eye on this company.
       
      • Like Like x 1
    21. Oto

      Oto Member

      Tinnitus Since:
      4/4/2020
      Cause of Tinnitus:
      Unknown ¿high frequencies pre-presbycusis?
    22. Greg Sacramento

      Greg Sacramento Member Benefactor Hall of Fame

      Tinnitus Since:
      April 2011
      Cause of Tinnitus:
      syringing and now somatic T dental work
      @Paulmanlike Details are out... 15,265,000 shares at $0.80/share. $12.5 million net. I wasn't far off on the amount of new issued shares, but I believe that they raised the price from $0.72 to $0.80 because they saw too much down pressure in after hours. I still would wait for a reverse split announcement before investment, because when a reverse spilt is announced which is now in review, the price will take another (larger) hit. Then after that, if the FDA gives positive guidance on Phase III along with the consumer medication application format being resolved, then I would consider buying.

      @grate_biff Any drug that requires a taper will be needed. It is said that AV-101 will not require a taper, as so far there has been no side effects. We will know more soon.
       
      • Informative Informative x 2
    23. Paulmanlike

      Paulmanlike Member Podcast Patron Benefactor Hall of Fame

      Tinnitus Since:
      2008
      Cause of Tinnitus:
      Noise
      I'm going to buy after the reverse stock split. Thanks Greg. Did you buy any FREQ stock?
       

Share This Page

Loading...